PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

被引：29
|
作者：
Gettinger, Scott [1 ]
Politi, Katerina [1 ]
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 18期
关键词：
IMMUNE ESCAPE; EXPRESSION; ACTIVATION; MUTATIONS;
D O I：
10.1158/1078-0432.CCR-16-1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. (C) 2016 AACR.
引用
收藏
页码：4539 / 4541
页数：3
相关论文
共 50 条
  • [41] Peptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer
    Bojko, Magdalena
    Wegrzyn, Katarzyna
    Sikorska, Emilia
    Ciura, Piotr
    Battin, Claire
    Steinberger, Peter
    Magiera-Mularz, Katarzyna
    Dubin, Grzegorz
    Kulesza, Adam
    Sieradzan, Adam K.
    Spodzieja, Marta
    Rodziewicz-Motowidlo, Sylwia
    TRANSLATIONAL ONCOLOGY, 2024, 42
  • [42] PD-1 inhibitors cause ILD in NSCLC patients with hypertension
    Reactions Weekly, 2022, 1925 (1) : 11 - 11
  • [43] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [44] Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
    Wang, Yanling
    Yang, Xiaoxuan
    Ma, Jia
    Chen, Shenglan
    Gong, Ping
    Dai, Ping
    HELIYON, 2024, 10 (05)
  • [45] Blocking the PD-1/PD-L1 axis for cancer therapy
    Drake, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S12 - S13
  • [46] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
    Meyers, D. E.
    Bryan, P. M.
    Banerji, S.
    Morris, D. G.
    CURRENT ONCOLOGY, 2018, 25 (04) : E324 - E334
  • [47] The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
    Yadav, Ritu
    Khatkar, Rinku
    Yap, Kenneth C-H
    Kang, Chloe Yun-Hui
    Lyu, Juncheng
    Singh, Rahul Kumar
    Mandal, Surojit
    Mohanta, Adrija
    Lam, Hiu Yan
    Okina, Elena
    Kumar, Rajiv Ranjan
    Uttam, Vivek
    Sharma, Uttam
    Jain, Manju
    Prakash, Hridayesh
    Tuli, Hardeep Singh
    Kumar, Alan Prem
    Jain, Aklank
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [48] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [49] SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
    Andreas I Papadakis
    Chong Sun
    Theo A Knijnenburg
    Yibo Xue
    Wipawadee Grernrum
    Michael Hölzel
    Wouter Nijkamp
    Lodewyk FA Wessels
    Roderick L Beijersbergen
    Rene Bernards
    Sidong Huang
    Cell Research, 2015, 25 : 445 - 458
  • [50] Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer
    Tangpeerachaikul, Anupong
    Bigot, Ludovic
    Friboulet, Luc
    Pelish, Henry E.
    CANCER RESEARCH, 2022, 82 (12)
12345